🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TOMORROW: Lung-MAP Advocacy Webinar Wed., May 14, 1-2 pm ET 1-hr webinar will review the trial's recent evolution & will engage advocacy partners in discussion to paint a clearer picture of current and emerging patient needs in #NSCLC. National Cancer Institute Register at: friendsofcancerresearch.org/event/lung-map…

#EAOnc Spring25 Meeting Ticiana Batista (Leal) Winship Cancer Institute of Emory University provides update on Lung-MAP 3.0- Biomarker Driven Master Protocol now with 10+ yrs of experience. We continue to have this #precisionmedicine trial opened Sylvester Comprehensive Cancer Center ECOG-ACRIN Cancer Research Group

Starting now! Lung-MAP Advocacy Webinar: Advocating, Accelerating, and Amplifying Lung Cancer Discovery. Join the live webinar: bit.ly/3EpG5Yx. #lcsm #lungcancer

.Lung-MAP allows patients to be enrolled in clinical trials conducted at small sites, which leads to better outcomes. Watch the webinar live and on-demand: bit.ly/43cRtzo #lcsm #luncancer

Many states, such as Louisiana and Illinois, are requiring insurance companies to cover cancer biomarker testing. Watch the Advocacy Webinar live and on-demand for Lung-MAP updates: bit.ly/43cRtzo #lcsm #biomarkertesting

2025 Lung-MAP Advocacy Webinar Trial updates + wisdom from #lungcancer advocacy org leaders: what's needed to advance treatments & better meet patient needs. #lcsm THANK YOU Bryan Faller LungCancerAmerica LUNGevity Foundation ICAN, International Cancer Advocacy Network MET Crusaders! Recording: youtube.com/watch?v=sFQh17…

Results from Lung-MAP sub-study S1900E will be presented as a rapid oral abstract (8515) at #ASCO25 on Mon, June 2, 9:00am CT, by Sukhmani (Suki) Padda MD. Abstract is at meetings.asco.org/abstracts-pres…. #LCsm Friends of Cancer Research Foundation for the National Institutes of Health Karen Reckamp, MD, MS David Gandara

Lung MAP annual update ASCO this morning. Mary Redman starts with a slide showing the "evolution of this public-private partnership, now with completion of 16 trials. Karen Reckamp, MD, MS National Cancer Institute Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network

Starting the #ASCO25 meeting with Lung-MAP Annual Update. A fantastic research group! Mary Redman, Karen Reckamp, MD, MS David Gandara Shirish Gadgeel Roy Herbst Ticiana Batista (Leal) Sara Goldberg Corey Langer Saiama Waqar SWOG Cancer Research Network NIH

Christian Rolfo presenting at Lung-MAP Annual Update at #ASCO25 the S1900J trial for patients with #NSCLC and #METamplification as primary driver treated with Amivantab sc. SWOG Cancer Research Network Foundation for the National Institutes of Health Ohio State Medical Oncology The James ASCO Shirish Gadgeel David Gandara RolfoLab

Monday is a busy day for SWOG Cancer Research Network at #ASCO25, with presentations on results from #lungcancer studies S1914, Lung-MAP S1900E, and S2302 Pragmatica-Lung! Full list is at swog.org/sites/default/…

#ASCO25 SWOG Cancer Research Network S2302 Pragmatica-Lung in adv non-small cell #lungcancer reports ramucirumab + pembrolizumab did not extend survival. Study is a model for large trials that launch quickly, are easy to conduct, rapidly enroll a highly representative population swog.org/news-events/ne…

Pragmatica-Lung has effectively reduced barriers to clinical trial participation and decreased clinical trial staff burden, showing its efficacy as a potential model for future studies. New findings announced at #ASCO25: asco.org/abstracts-pres…

Great to see results from Lung-MAP S1900E 📍Despite smaller subgroups, it’s quite clear that the cohort with STK11 co mutation does not respond as well with sotorasib. Congratulations to Dr.Padda and team. #lcsm #ASCO25

S1800E is a Lung-MAP non-match sub-study. Randomized ph 2/3: docetaxel & ramucirumab w or w/o cemiplimab in patients w previous platinum-based chemo & IO for stage IV or recurrent NSCLC. PI: Saima Waqar, MD, MSCI WashU Medicine Division of Oncology Siteman Cancer Center

Lung MAP annual update at ASCO25 -Meeting the "unmet needs" with 3 active trials in MET space. Lung-MAP National Cancer Institute Foundation for the National Institutes of Health

A recording of the May 14th Lung-MAP Advocacy Webinar is online at bit.ly/43cRtzo. Featuring a panel discussion with Friends of Cancer Research's Ryan Hohman, LUNGevity Foundation's Andrea Stern Ferris, Marcia Horn of Exon 20 Group, a multistakeholder organization & ICAN, International Cancer Advocacy Network, and LungCancerAmerica's Kim Norris. #lcsm #lungcancer SWOG Cancer Research Network

The The ASCO Post discusses #ASCO25 presentations on S2302 Pragmatica-Lung, a groundbreaking phase 3 trial launched based on findings of phase 2 Lung-MAP sub-study S1800A. #NSCLC #lcsm

Thank you to Marcia Horn, representing METCrusaders (and SWOG Cancer Research Network patient advocate) for sharing her insights & wisdom in the Lung-MAP webinar "Advocating, Accelerating, and Amplifying Lung Cancer Discovery." Recording is at bit.ly/43cRtzo

Lung-MAP 3.0’s easier genetic screening process means Lung-MAP will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S. lung-map.org Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network National Cancer Institute